第 10 年的结核病药物加速计划：我们学到了什么？
The Tuberculosis Drug Accelerator at year 10: what have we learned?
机构信息
Tufts University, Boston, MA, USA.
GlaxoSmithKline, Tres Cantos, Spain.
出版信息
Nat Med. 2021 Aug;27(8):1333-1337. doi: 10.1038/s41591-021-01442-2.
Abstract
The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in TB drug discovery by breaking down barriers among competing labs and institutions, has reached the 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for application of similar models to other diseases.
摘要
结核病药物加速计划是一个旨在通过打破竞争实验室和机构之间的障碍来促进结核病药物发现合作的实验，已经达到了 10 年的里程碑。我们回顾了该联盟的成就、优势和局限性，并主张将类似的模式应用于其他疾病。
相似文献
1
The Tuberculosis Drug Accelerator at year 10: what have we learned?
Nat Med. 2021 Aug;27(8):1333-1337. doi: 10.1038/s41591-021-01442-2.
2
NOC chemistry for tuberculosis-further investigations on the structure-activity relationships of antitubercular isoxazole-3-carboxylic acid ester derivatives.
ChemMedChem. 2010 Oct 4;5(10):1667-72. doi: 10.1002/cmdc.201000169.
3
Drugs and drug development for chemotherapy of leprosy and tuberculosis, including M. avium infections.
Trop Med Parasitol. 1990 Sep;41(3):341-3.
4
A review on various heterocyclic moieties and their antitubercular activity.
Biomed Pharmacother. 2011 Jul;65(4):244-51. doi: 10.1016/j.biopha.2011.04.005. Epub 2011 May 30.
5
Towards new tuberculosis drugs.
Biochem Soc Trans. 2007 Nov;35(Pt 5):1321-4. doi: 10.1042/BST0351321.
6
Challenges in tuberculosis drug research and development.
Nat Med. 2007 Mar;13(3):290-4. doi: 10.1038/nm0307-290.
7
Lessons from seven decades of antituberculosis drug discovery.
Curr Top Med Chem. 2011;11(10):1216-25. doi: 10.2174/156802611795429158.
8
The added effect of thioridazine in the treatment of drug-resistant tuberculosis.
Int J Tuberc Lung Dis. 2012 Dec;16(12):1706-8; author reply 1708-9. doi: 10.5588/ijtld.12.0616.
9
Exploration of potential inhibitors for tuberculosis via structure-based drug design, molecular docking, and molecular dynamics simulation studies.
J Comput Chem. 2021 Sep 15;42(24):1736-1749. doi: 10.1002/jcc.26712. Epub 2021 Jul 2.
10
Fighting tuberculosis: an old disease with new challenges.
Med Res Rev. 2005 Jan;25(1):93-131. doi: 10.1002/med.20017.
引用本文的文献
1
Mycobacterium tuberculosis biology, pathogenicity and interaction with the host.
Nat Rev Microbiol. 2025 Jun 30. doi: 10.1038/s41579-025-01201-x.
2
Strategies for shortening tuberculosis therapy.
Nat Med. 2025 Jun;31(6):1765-1775. doi: 10.1038/s41591-025-03742-3. Epub 2025 Jun 13.
3
Voices of Nanomedicine: Blueprint Guidelines for Collaboration in Addressing Global Unmet Medical Needs.
ACS Nano. 2025 Jan 28;19(3):2979-2991. doi: 10.1021/acsnano.4c13513. Epub 2025 Jan 10.
4
How Should we Teach Medicinal Chemistry in Higher Education to Prepare Students for a Future Career as Medicinal Chemists and Drug Designers? - A Teacher's Perspective.
ChemMedChem. 2025 Jan 14;20(2):e202400791. doi: 10.1002/cmdc.202400791. Epub 2024 Nov 20.
5
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0071624. doi: 10.1128/aac.00716-24. Epub 2024 Sep 30.
6
Mycobacterial biotin synthases require an auxiliary protein to convert dethiobiotin into biotin.
Nat Commun. 2024 May 16;15(1):4161. doi: 10.1038/s41467-024-48448-1.
7
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits.
Proc Natl Acad Sci U S A. 2024 Apr 2;121(14):e2321336121. doi: 10.1073/pnas.2321336121. Epub 2024 Mar 26.
8
Redirecting raltitrexed from cancer cell thymidylate synthase to phosphopantetheinyl transferase.
Sci Adv. 2024 Mar 15;10(11):eadj6406. doi: 10.1126/sciadv.adj6406.
9
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.
Nat Rev Drug Discov. 2024 May;23(5):381-403. doi: 10.1038/s41573-024-00897-5. Epub 2024 Feb 28.
10
A spotlight on the tuberculosis epidemic in South Africa.
Nat Commun. 2024 Feb 12;15(1):1290. doi: 10.1038/s41467-024-45491-w.
本文引用的文献
1
Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Mutant in a Mouse Model of Tuberculosis.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02418-20.
Zotero 插件